Last reviewed · How we verify
Sabin IPV+ bOPV+ bOPV
This is a combination polio vaccine containing inactivated poliovirus (IPV) and bivalent oral poliovirus vaccine (bOPV) that stimulates immune responses against poliovirus types to prevent poliomyelitis.
This is a combination polio vaccine containing inactivated poliovirus (IPV) and bivalent oral poliovirus vaccine (bOPV) that stimulates immune responses against poliovirus types to prevent poliomyelitis. Used for Prevention of poliomyelitis (polio) in infants and children.
At a glance
| Generic name | Sabin IPV+ bOPV+ bOPV |
|---|---|
| Sponsor | Zhejiang Provincial Center for Disease Control and Prevention |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine combines inactivated poliovirus vaccine (IPV), which contains chemically inactivated poliovirus particles administered by injection, with bivalent oral poliovirus vaccine (bOPV), which contains live attenuated poliovirus types 1 and 3 administered orally. Together, these components induce both systemic and mucosal immunity against poliovirus, providing protection against polio infection and transmission.
Approved indications
- Prevention of poliomyelitis (polio) in infants and children
Common side effects
- Local injection site reactions (pain, redness, swelling)
- Fever
- Irritability or fussiness
- Mild gastrointestinal symptoms
Key clinical trials
- Study of Concomitant Administration of the sIPV and DTaP or MMR (PHASE4)
- Study to Evaluate Eupolio(IPV)'s Safety, Long-term Protective Effect and Boosting Effect of One Booster Dose in the Three Primary Vaccination Plus Boosting Schedule, and Protective Effect in the Schedule With Bivalent OPV in Infants (PHASE3)
- A Study to Evaluate Safety and Immunogenicity of Sequential Vaccination of Sabin Inactivated Poliomyelitis Vaccine (Vero Cell) and Live Attenuated Poliomyelitis Vaccine in Healthy 2-month-old Infants (PHASE3)
- Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPV (PHASE3)
- Inactivated Poliovirus Vaccine (IPV) With or Without E.Coli Double Mutant Heat-Labile Toxin (dmLT) Challenge Study in Healthy Adults (PHASE1)
- Immunogenicity and Safety of the Booster Dose of Polio Vaccine With Different Primary Sequential Schedules in China (PHASE4)
- A Study to Evaluate the Safety and Immunogenicity of Oral Polio Vaccine Type 2 in Infants and Children (PHASE4)
- Immunogenicity and Safety Evaluation of Different Sequential Immunization Strategies by Sabin IPV and bOPV in Chinese Infants (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |